2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1724

Pandemic Influenza Immunization in Primary Antiphospholipid Syndrome (PAPS): A Trigger to Autoantibody Production?
Abstract Number: 1604

Parity and the Risk of Developing Rheumatoid Arthritis: Results From the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study
Abstract Number: 842

Partial and Complete Recovery From Proteinuria in Lupus Nephritis Patients Receiving Standard of Care Treatment
Abstract Number: 1537

Pathogenesis of Atherosclerosis in Granulomatosis Polyangiitis
Abstract Number: 504

Pathogenic Autoantibodies to the Anti-Muscarinic Type 3 Receptor Act by Competitive Inhibition of Acetylcholine-Mediated Receptor Signalling in Sjögren’s Syndrome
Abstract Number: 409

Pathway Analysis of Genome-Wide Association Studies On Rheumatoid Arthritis
Abstract Number: 2510

Patient and Provider Factors Associated with Compliance with Rheumatoid Arthritis Treatment Recommendations
Abstract Number: 2106

Patient Characteristics Associated with Discrepancies in Evaluator-Reported and Patient-Reported Outcomes in U.S. Veterans with Rheumatoid Arthritis
Abstract Number: 1527

Patient Global Assessments for Disease Activity Are Predictive of Future Flare in Granulomatosis with Polyangiitis (Wegener’s)
Abstract Number: 1468

Patient Perspective Informs Core Sets, Constructs of Metrics and Communication Tools for Patients with Connective Tissue Disease Related Interstitial Lung Disease
Abstract Number: 488

Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
Abstract Number: 2098

Patient Report Outcomes Variance Between Centers Is Much Lower Than Physician and Laboratory Assessed Measures of Rheumatoid Arthritis Activity: Results From a Multinational Study
Abstract Number: 1526

Patient Reported Outcomes in ANCA-Associated Vasculitis. A Prospective Comparison Between Birmingham Vasculitis Activity Score and Routine Assessment of Patient Index Data 3
Abstract Number: 2606

Patient Reported Outcomes in Early Arthritis Patients
Abstract Number: 1925

Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].